Kymera IPO Presentation Deck

Issuer Ticker / Exchange Offering Size Concurrent Private Placement Price Range Gross Proceeds Over-Allotment Option Expected Pricing Use of Proceeds Lock-Up Period Bookrunners KYMERA Offering Summary Kymera Therapeutics, Inc. KYMR/ Nasdaq Global Market 7,360,000 shares of common stock (100% Primary) **500,000 shares of common stock, with the option to purchase ~75,000 additional shares if the over- allotment option is exercised in full $16 - $18 per share ~$134MM (at midpoint of price range, includes $8.5MM in proceeds from concurrent private placement and excluding option to purchase additional shares) 15% (100% primary) Thursday, August 20th (Post-market close) * Development of the IRAK4 program Development of the IRAKIMID program • Development of the STAT3 program . Continued expansion of the platform technology, preclinical studies for research stage programs, working capital and other general corporate purposes 180 days for the Company, directors, officers and substantially all other pre-IPO share and option holders Morgan Stanley, BofA Securities, Cowen, Guggenheim Securities

View entire presentation